U.S. markets close in 2 hours 39 minutes

UnitedHealth Group Incorporated (UNH)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
356.80+5.96 (+1.70%)
As of 1:20PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close350.84
Open350.81
Bid355.94 x 900
Ask356.32 x 800
Day's Range350.74 - 360.88
52 Week Range187.72 - 367.95
Volume1,943,142
Avg. Volume3,231,180
Market Cap338.544B
Beta (5Y Monthly)0.74
PE Ratio (TTM)20.50
EPS (TTM)17.41
Earnings DateApr 13, 2021 - Apr 19, 2021
Forward Dividend & Yield5.00 (1.43%)
Ex-Dividend DateDec 04, 2020
1y Target Est393.79
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
6% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Healthcare ETFs in Focus on UnitedHealth's Solid Q4 Earnings
    Zacks

    Healthcare ETFs in Focus on UnitedHealth's Solid Q4 Earnings

    UnitedHealth Group (UNH) reported better-than-expected fourth-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues.

  • UnitedHealth 4Q Sales Top Street Estimates Driven By Optum Business
    SmarterAnalyst

    UnitedHealth 4Q Sales Top Street Estimates Driven By Optum Business

    UnitedHealth Group reported better-than-expected fourth-quarter results despite a spike in pandemic-led healthcare costs. The healthcare giant’s 4Q sales rose 7.5% to $65.5 billion year-on-year, exceeding consensus estimates of $65.1 billion. Shares closed at $350.84 on Jan. 20. UnitedHealth (UNH) posted 4Q adjusted earnings of $2.52 per share, which beat analysts’ estimates of $2.40 per share. The company’s 4Q net EPS (earnings per share) of $2.30 fell from the $3.68 posted during the same quarter last year. Its adjusted EPS of $2.52 per share declined from $3.90 in 4Q19. This decline in earnings per share was largely related to higher healthcare costs due to Covid-19, the company said. For FY20, revenue rose 6% to $257.1 billion year-on-year, led by a 21% uptick in sales at its Optum business. Optum is UnitedHealth’s information technology-enabled health services business that serves different dimensions of the healthcare system including care providers, life sciences companies, and consumers. (See UNH stock analysis on TipRanks) UnitedHealth’s CEO, David S. Wichmann, commented, “We are grateful for the human spirit and resolve of our people, including our 125,000 clinicians who, with other frontline health care workers, demonstrated extraordinary collaboration, compassion and innovation.” The company affirmed its FY21 earnings outlook and expects net earnings of between $16.90 to $17.40 per share and adjusted net earnings of between $17.75 to $18.25 per share. According to UnitedHealth, this outlook includes a negative impact of approximately $1.80 per share due to Covid-19 that included testing and treatment costs and people deferring healthcare in 2020. Following the 4Q results, Oppenheimer analyst Michael Wiederhorn reiterated a Buy rating on the stock and set a price target of $375. “The company’s Optum business is a nice complement to its core managed care operations and continues to account for a large share of earnings,” Wiederhorn commented in a note to investors. Furthermore, UNH’s vertical integration strategy strengthens the company’s competitive positioning across many areas of the healthcare landscape.” Overall, analysts are bullish about the stock and the consensus is a Strong Buy with 16 analysts suggesting a Buy and 2 analysts recommending a Hold. The average price target of $396.44 implies 13% upside potential to current levels. Related News:Aclaris Explodes 220% On ‘Positive Data’ From Rheumatoid Arthritis TrialAkzo Nobel Enters Tikkurila Takeover Battle With $1.7B BidMasterCraft Is Going Digital For Its Dynamic Boat Show Season More recent articles from Smarter Analyst: 2 “Strong Buy” Penny Stocks That Could See Outsized Gains United Airlines Posts Wider-Than Feared Loss of $1.9B In 4Q; Street Says Hold Thursday’s Pre-Market: Here’s What You Need To Know Before The Market Opens Inovio Sinks 7% After Pricing Of $150.5M Share Offering; Street Says Hold